Xenetic Biosciences Inc. (XBIO)
| Bid | 2.45 |
| Market Cap | 4.19M |
| Revenue (ttm) | 2.5M |
| Net Income (ttm) | -3.96M |
| EPS (ttm) | -2.57 |
| PE Ratio (ttm) | -1.06 |
| Forward PE | -5.17 |
| Analyst | n/a |
| Ask | 3.21 |
| Volume | 11,656 |
| Avg. Volume (20D) | 6,631 |
| Open | 2.50 |
| Previous Close | 2.55 |
| Day's Range | 2.47 - 2.72 |
| 52-Week Range | 2.20 - 5.20 |
| Beta | 2.31 |
About XBIO
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor ...
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · accessnewswire.com
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (S...
1 month ago · accessnewswire.com
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial ResultsEncouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers Strategic focus on exploratory investigator-initiated clinical studie...
